July 25, 2012
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Questcor Pharmaceuticals (Nasdaq: QCOR ) fell 13% today after reporting better-than-expected earnings. Wait, what?
So what: It's all about the details of the earnings report. Revenue rose 144.6% from a year ago to $112.5 million, topping estimates, and adjusted earnings per share were $0.69, six cents above estimates.
But the problem today is the number of rebated prescriptions of Acthar, the company's $23,000-per-vial drug. One estimate from ThinkEquity estimated that 94 MS prescriptions were rebated for a total of 1,167 including paid, but the actual number was 41 for a total of 1,151 total prescriptions. The trend for nephritic syndrome was similarly disappointing.
Now what: I wouldn't be too worried about the rebate miss, the company has been increasing paid prescriptions at a rapid rate, and both the top and bottom lines were better than expected. Shares now trade at 10 times forward earnings, and if current trends continue, that could be a great deal for investors. Investors can often freak out about small details in earnings reports, but I think the overall picture looks strong, and shares cam move higher from here.
Interested in more info on Questcor Pharmaceuticals? Add it to your Watchlist.
More Expert Advice from The Motley Fool
Questcor is one of the most debated names in all of biotech. Its premium priced drug, Acthar, is growing at a torrid pace -- and minting money in the process. However, recent events have created significant doubts about Questcor's future. Will insurance companies continue to cover the drug? Will a government investigation lead to huge fines? We highlight these high-profile issues inside our brand new premium research report on Questcor
. In it, you'll learn about the key opportunities and threats facing the company, as well as multiple reasons to buy and sell the stock. We're providing a full year of analyst updates as key news hits, so make sure to claim a copy today by clicking here now